Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke

US11946938B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Ursula-Henrike Wienhues-Thelen · Krailling, DE
• Johann Karl · Peißenberg, DE
• Peter Kastner · Murnau am Staffelsee, DE
• Vinzent Rolny · Munich, DE
• Andre Ziegler · Läufelfingen, CH
• David Conen · Southcote, CA

Key dates

• Filing date: Jun 12, 2020
• Grant date: Apr 2, 2024
• Expiry date: Jun 12, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.